What the FDA labels say about taking them together
Lovastatin and voriconazole
Lovastatin's FDA label of May 6, 2026 names voriconazole in its contraindications section; voriconazole's label does not name lovastatin itself but warns about its class (Statins). The lovastatin label: “Concomitant administration with strong CYP3A4 inhibitors.”
Check it at the source: the lovastatin FDA label on DailyMed (effective May 6, 2026, Lupin Pharmaceuticals, Inc.); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the lovastatin label say about voriconazole?
Lovastatin label, contraindicationsConcomitant administration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistat-containing products) (see WARNINGS, Myopathy/Rhabdomyolysis ).
Lovastatin label, warningsThese include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products.
Source: FDA drug label (Lovastatin), Lupin Pharmaceuticals, Inc., effective May 6, 2026 (SPL set df7ddf4f-d569-431e-81f1-9129d7043150), via openFDA; the full label on DailyMed
What does the voriconazole label say about lovastatin?
Voriconazole's label does not name lovastatin itself; it warns about its class (Statins):
Voriconazole label, drug interactionsHMG-CoA Reductase Inhibitors (Statins) (CYP3A4 Inhibition) In Vitro Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure) Frequent monitoring for adverse reactions and toxicity related to statins.
Voriconazole label, drug interactionsIncreased statin concentrations in plasma have been associated with rhabdomyolysis.
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lovastatin | Voriconazole | |
|---|---|---|
| Labeled for | High cholesterol, Heart attack and coronary artery disease | Fungal infections |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0436 per tablet 20 mg tablet | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once